Loading stock data…
$7.40-0.57 (-7.15%)
enVVeno Medical Corporation, a medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease in the United States.
enVVeno Medical Corporation in the Healthcare sector is trading at $7.27 with a market capitalization of $7M. Wall Street consensus targets $30.00 (1 analysts), implying a +312.6% move over the next 12 months. The stock is currently near its 52-week low of $7.01, remaining 31.4% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$3.80M↑ | -$4.06M↓ | -$4.01M↑ | -$4.88M↑ | -$7.05M |
| Net Income | -$3.60M↑ | -$3.85M↓ | -$3.74M↑ | -$4.54M↑ | -$6.69M |
enVVeno Medical Corporation, a medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease in the United States. The company's lead product is the VenoV...